Targeting the activation of immune cells by abnormal proteins such as β-amyloid or α-synuclein and the resulting neuroinflammatory response can be a potential strategy for treating neurodegenerative diseases such as Alzheimer’s or Parkinson’s [31,32]. The gene discussed is SNCA; the disease is Parkinson disease.